Our team has internally been sharing ways to support people affected by the crisis in Ukraine, so we thought we’d share some of...

1xBit is glad to announce that the BIG 5 event is still ongoing, including additional prizes. Participants in the first prize draw have received their awards and now is your chance to be among the luckiest as the tournament continues.  There is currently a diverse choice of events accessible to choose from. The events revolve […]

Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany), Mar 9, 2022 - (JCN Newswire) - NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM's neoantigen program assets.

Under the agreement, NOI will acquire VAXIMM's neoantigen vaccine-related patents, license the requisite manufacturing patents, and will take over several existing contracts with key collaborators and partners. Financial terms of the agreement have not been disclosed. In 2019, the companies entered into a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines. VAXIMM retains rights to its first-in-class oral T-cell activation platform technology and all other product candidates, including VXM01, which is being developed for the treatment of glioblastoma.

Commenting on the announcement, Richard Stratford, CEO of NOI, said, "We believe this is a transformative transaction for NOI/NEC. With it, NOI/NEC has acquired the rights to an attractive delivery platform with broad therapeutic potential in oncology and other areas. Following this acquisition, we expect to initiate the first clinical study delivering personalized neoantigens during 2022, which is an important milestone. Our unique artificial intelligence (AI) technology is focused on several attractive areas of unmet medical need with major market potential, and we now have the components in place to fully realize this significant commercial opportunity."

Thomas D. Szucs, MD, Chairman of the Board of VAXIMM, said, "I am excited to see the progress that has been made in advancing our neoantigen program, already with the strong support of NEC as partner and investor. I congratulate the VAXIMM team, under Dr. Lubenau's leadership, for bringing this important project to clinical testing stage. We are delighted that the NOI team will now take this program forward into the clinic with the goal of bringing a novel therapy to patients in desperate need of more treatment options."

Dr. Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through development and hopefully to the market to help patients. The first project from our earlier collaboration utilizing NEC's AI platform has received clinical trial approval in Europe, and we are excited that NEC will be putting its resources behind this and future neoantigen vaccine programs derived from VAXIMM's novel technology."

Motoo Nishihara, Executive Vice President, CTO (Chief Technology Officer) and Member of the Board, NEC Corporation, said, "Cancer and infectious diseases are two of the most serious healthcare challenges, with millions of new cases diagnosed worldwide annually. NEC's core AI technology is well positioned for the development of personalized medicines, and we are strongly committed to delivering effective treatments for cancer patients and infectious diseases. We are confident that this acquisition of assets from VAXIMM will enable us to further develop our AI-optimized and personalized therapies to benefit the health of individual patients worldwide."

The transaction expands NEC's neoantigen drug development pipeline by broadening its focus into several compelling therapeutic areas with high unmet medical need. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range of cancer-related antigens. The platform allows for fast and scalable manufacturing of personalized T-cell cancer vaccines and may overcome key challenges faced by many other approaches.

About NEC OncoImmunity AS

NEC OncoImmunity AS is an AI driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy, in addition to infectious disease vaccines. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at https://www.oncoimmunity.com/.

About NEC's AI Drug Development Business

For more information, please visit https://www.nec.com/en/global/solutions/ai-drug/

About NEC's Neoantigen Prediction System

NEC's neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets. These targets are carefully analyzed using proprietary machine learning algorithms that include in-house HLA binding and antigen presentation AI tools to evaluate the likelihood of eliciting a robust and clinically relevant T-cell response. With NEC OncoImmunity now onboard, NEC continues to strengthen its top class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide. For more information, visit NEC at www.nec.com.

About VAXIMM

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range of cancer-related antigens. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM has recently licensed its neoantigen program assets to NEC OncoImmunity, a subsidiary of NEC Corporation. VAXIMM's platform allows for fast manufacturing of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM's existing programs.

VAXIMM's investors include: BB Biotech Ventures, BCM Europe, BioMedPartners, CMS, M Ventures, NEC and CSV as well as Sunstone Life Science Ventures. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company's development activities. For more information, please visit www.vaximm.com.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comNEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM's neoantigen program assets.

GameFi—also known as play-to-earn—is the dynamic combination of gaming and decentralised finance. Blockchain technology has given ownership back to players, and they're reaping the benefits. This trend in the crypto space has given rise to a flurry of projects, each seeking to stand out from the crowd.

One of these up and coming projects is Samurai Legends—a fully-functional play-to-earn ecosystem with big ideas. The ecosystem's first addition, Samurai Rising, already supports an active player base that collectively earns thousands of dollars a day, making it exceptionally popular in developing nations such as the Philippines.

The project's real promise, however, lies in its future. While many debutants to the GameFi scene have gained traction, few have been as ambitious as Samurai Legends. Fundamentally, the project aims to evolve from a simple card game into a persistent player-owned world full of strategy, warfare and even political intrigue.

This transformation will begin to unravel on March 16th, when the project's two virtual currencies ($SMG and $KOKU) start to launch across numerous platforms.

Chain Pixel Labs

Despite these grand aspirations, the team behind Samurai Legends has humble beginnings. Samurai Rising originally belonged to RisingSun—a bootstrapped collective of like-minded individuals. The success of Samurai Rising paired with vital strategic partnerships has given rise to a fully-fledged GameFi studio—Chain Pixel Labs.

Thanks to these partnerships, the team has transitioned from part-time to full-time and has the funding to complete their visionary roadmap, regardless of market conditions. In particular, the studio's partnership with Crypto Gaming United has promised an influx of 25,000 additional players and full strategic backing for the long haul. 

The newfound CEO of Chain Pixel Labs, David, has joined the growing list of tech engineers to quit coveted FAANG positions for a once in a generation chance at building the future of finance. A project once constricted by time constraints and economic realities now has everything it needs to not just function—but thrive. 

GameFi in feudal Japan. Enter the samuraiverse.

Twitter: https://twitter.com/samuraiverse

Discord: https://discord.gg/samurailegends

Website: https://samurailegends.io

Telegram: https://t.me/samurailegends

SolidProof KYC: https://github.com/solidproof/kyc-certificates/blob/main/KYC_Certificate_RisingSun.png

Media Contact: [email protected]

Disclaimer:

The information provided in this release is not investment advice, financial advice or trading advice. It is recommended that you practice due diligence (including consultation with a professional financial advisor before investing or trading securities and cryptocurrency.

Submitted by: [email protected]

Tentacular is shaping up to be a monstrously good time.

The highly-anticipated third addition of the Coin Rivet podcast is live! This week’s episode features five-time World Series of Poker bracelet winner Brian Rast, who reveals a healthy passion in Bitcoin and the crypto market.

The post Quest Team Shooter ‘NERF Ultimate Championship’ to Enter Closed Beta Soon, Signups Here appeared first on Road to VR.

According to the project's developers, the Tasmanian Devils are carnivorous animals initially found in the islands of Tasmania. In recent years, these animals have been introduced to other parts of the globe, including Australia. 

However, the Tasmanian Devil's global population has vastly reduced in the past two decades, and there is fear that the creatures are on the brink of extinction. The population reduction is because of infectious cancer called Devil Facial Tumor Disease (DFTD). Hence, the Tasmanian Devils NFT network is on a mission to collect funds and protect these little devils, launching an NFT collection with around 5000 unique devils. The 5000 devils are distinct in utility. 

According to the Tasmanian Devils NFT network, each NFT has eight traits and bears benefits to holders. They can give special access to the discord channel, and help holders get exclusive merchandise. You can also participate in exclusive airdrops and stand a chance to win $50k and some art. 

Profits generated within this project will be used to save the creatures. For instance, the profits fund research projects that find cures for the DFTD disease. The Tasmanian Devils network will donate $50 thousand to 'The Tasmanian Devil Appeal' after successfully selling out, and they will be expanding their support for Tasmanian protection as it grows. 

The Discord Milestone and Whitelisting

While they announce their project, the Tasmanian Devil NFT network also announces their recent discord milestone. According to their Twitter page, the Tasmanian Devil network reached 1000 OG members on March 5th, 2022. The network began inviting people to their discord server on February 24th, and by March 5th, the OG spots were full.

Tasmanian Devils NFT network planned to make their discord open for the public once they reached 1000 OG members. Hence, anyone can join their discord channel and interact with the community. Moreover, by joining the Tasmanian Devil discord and following instructions issued in the channel, one may have a higher chance of getting whitelisted. Consequently, being whitelisted gives you an early chance to mint NFTs.

Community is the Center

Tasmanian Devils NFT network notes that while the animals are the heart of this project, the community is the backbone. The Tasmanian Devils community will make major decisions on an upcoming comic story. The Tasmanian Devils community will make major decisions. The network also partners with celebrities and other networks to achieve objectives. 

About Tasmanian Devil NFT

Tasmanian Devil NFT is a blockchain-based NFT platform created to help in protecting Tasmanian devils from extinction. This platform introduces a vast collection of features to help generate funds for research on the disease that is killing Tasmanian devils. The team, which involves Oliver Walker, Peter Cooper, and Leo Cooper, focuses on protecting the little carnivorous creatures.

| Website | Discord | Twitter | Instagram | 

Merging the principles of decentralization and the open web paves way for democratic concepts like digital inclusion and free expression. As crypto enthusiasts, we all want projects to abide by what decentralization is all about, giving every individual a chance to be part of the project’s growth, as opposed to relying on select gatekeepers or […]

 – March 8, 2022 – Metacurio, the leading NFT creative agency for A-list talent and global brands, today announced it is producing an historic NFT collaboration with Ukrainian star Wladimir Klitschko and legendary artist WhIsBe. The NFT series, which drops Wednesday, features four NFT editions of the artist's “Vandal Gummy” bears in the colors of the Ukrainian flag. The collection will be titled “Vandalz for Ukraine: WhIsBe x Wladimir Klitschko.”

Leading NFT marketplace OpenSea will be hosting the drop. Three editions of “Vandal Gummy” bear NFTs will be available at different price points of $100, $1,000, and $10,000. There will be a 1-of-1 NFT selling for $1MM. All funds from the drop will go directly toward supporting the people of Ukraine during this crisis, with participating partners waiving their fees. The drop sale will last for three weeks starting tomorrow.

“This is not just a chance to own an astonishing piece of art history but, more importantly, an easy way to directly support the people of Ukraine who are in crisis right now,” said Metacurio Founders Sophie Watts and Jeff Hood in a joint statement. “We are humbled to support this cause in every way possible.” 

“It is a magnificent initiative: a support through art, a superb "suppart" at the service of people who suffer,” says Wladimir Klitschko. “Art can be beautiful on many levels when used to serve humanity.”

“I'm grateful for the opportunity to be of service for the greater good,” noted WhIsBe. “It's incredible to be able to use my art and this emerging technology to help others in need and provide immediate relief to any location in the world.”

Wladimir Klitschko, founder, lecturer and longest-reigning heavyweight boxing world champion, and his brother Vitali Klitschko, Mayor of Kyiv and former world boxing champion, have been the faces of Ukrainian resistance to Russia's invasion along with Ukrainian President Volodymyr Zelensky. All proceeds will go to Red Cross Ukraine and UNICEF, ensuring that funds from the NFT sale go directly to the resources most direly needed by Ukraine in its current defense against Russian forces. 

Contemporary artist WhIsBe has established a formidable reputation in not just the renegade world of street art, but also the mainstream art world encompassing the museum, gallery and arena of public installations. WhIsBe entered into the crypto space back in 2017 and became one of the first fine artists to enter into the NFT space in early 2020. He has since made his mark in the community by selling the first non-auction 7 figure NFT and becoming one of the top 10 NFT artists in the world. His moniker, shorthand for “What is Beauty,” is at once innocuous and sweet, while introducing more substantive themes of cultural examination and subversion that underline much of his body of work.

About Metacurio

Metacurio is the world's leading web3 creative agency for leading A-list talent and global brands. The company partners with clients to create boundary-pushing NFT experiences and delivers full-service infrastructure, strategy, and support for each drop. Established in 2021, Metacurio was founded by Blocksquared founder Jeff Hood and former STX Entertainment President Sophie Watts.

Media contact: [email protected]

Company contact: [email protected]

Yield farming has been gaining traction as one of the most lucrative crypto investment strategies with high liquidity. It gives crypto investors a greater chance to increase their revenue and earn higher ROI. Yield Farming happens through decentralized applications (dapps) that run on a blockchain network. They have no third party involved and eliminate the […]

In celebration of International Women’s Day and National Women’s Month, Sit-Up Philippines, DynaQuest, and the Philippine Blockchain Association recognize the 10 Women Innovators in Blockchain from the Philippines.

The post Philippine Women Innovators in Blockchain 2022 #BreakTheBias appeared first on BitPinas.